



(86) Date de dépôt PCT/PCT Filing Date: 2000/09/18
(87) Date publication PCT/PCT Publication Date: 2001/03/29
(45) Date de délivrance/Issue Date: 2008/02/26
(85) Entrée phase nationale/National Entry: 2001/05/16
(86) N° demande PCT/PCT Application No.: JP 2000/006351
(87) N° publication PCT/PCT Publication No.: 2001/021788
(30) Priorité/Priority: 1999/09/17 (JP11/263778)

(51) Cl.Int./Int.Cl. *C12N 15/09* (2006.01),
C07K 14/47 (2006.01), *C07K 14/52* (2006.01),
C07K 16/24 (2006.01), *C12N 5/10* (2006.01),
C12P 21/08 (2006.01), *G01N 33/53* (2006.01),
G01N 33/577 (2006.01)

(72) Inventeur/Inventor:
GOITSUKA, RYO, JP

(73) Propriétaire/Owner:
JAPAN SCIENCE AND TECHNOLOGY
CORPORATION, JP

(74) Agent: OGILVY RENAULT LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : MOLECULES TRANSDUISANT UN SIGNAL SPECIFIQUE DE CELLULE BASOPHILE/MASTOCYTE ET
LEURS ADN COMPLEMENTAIRES

(54) Title: MAST CELL-SPECIFIC SIGNAL TRANSDUCER AND CDNA THEREOF

(57) **Abrégé/Abstract:**

The present invention provides a signal transducer specifically expressed in mouse mast cells that has the amino acid sequence of SEQ ID No. 2, a signal transducer specifically expressed in human mast cells that has the amino acid sequence of SEQ ID No. 4, polynucleotides encoding these proteins, an expression vector involving these polynucleotides, transformed cells induced by these expression vectors, and antibodies against the foregoing proteins. The signal transducer provided in the present invention is useful for screening of novel medicines against allergic diseases.



ABSTRACT

The present invention provides a signal transducer specifically expressed in mouse mast cells that has the amino acid sequence of SEQ
5 ID No. 2, a signal transducer specifically expressed in human mast cells that has the amino acid sequence of SEQ ID No. 4, polynucleotides encoding these proteins, an expression vector involving these polynucleotides, transformed cells induced by these expression vectors, and antibodies against the foregoing proteins. The signal transducer
10 provided in the present invention is useful for screening of novel medicines against allergic diseases.

DESCRIPTION

Mast Cell-Specific Signal Transducer and cDNA thereof

5

Technical Field

10 The present invention relates to a signal transducer specifically expressed in mouse and human mast cell, and polynucleotides (cDNAs) encoding this protein molecule. More particularly, the present invention relates to a novel protein that is useful, for example, as a target molecule for screening a therapeutic agent for allergic diseases, and various
15 genetic engineering materials useful for production and functional analysis of this protein.

Background Art

20

 The type-I allergic response is a complicated immune reaction induced by release of granules containing histamine and serotonin through cross-linking of high affinity IgE receptors mainly expressed in the mast cell and basophilic leukocytes with IgE antibodies and allergens.
25 This reaction has been elucidated to be composed of the following three stages:

 A) An initial stage including production of cytokines such as IL-4 and IL-5 from T cell by stimulation of allergens, production of the IgE antibody from B cell, and differentiation and proliferation of the mast cells induced
30 by production of the cytokines;

 B) An intermediate stage from cross-linking of Fcε receptors by the IgE antibody and allergen to degranulation of the mast cell; and

 C) A later stage such as enhanced vascular permeability by

histamine and serotonin after degranulation.

The inventors of the present invention have isolated an adapter molecule BASH that is specifically expressed in B cell (J. Immunol., 5 161:5804-5808, 1998). This BASH has a similar molecular structure to SLP-76 (J. Biol. Chem., 270:7029-7032, 1995) that is expressed in T cell, and indicates the presence of a family of signal transducers specific to hemopoietic immunoreceptors through structural and functional analysis.

10

While suppression of IgE antibody production (Primary Stage) by B cell using a hyposensitization therapy, or suppression of the later stage by administration of anti-histaminic agent have been used today for treating allergies, neither of them serves as an effective therapy in the current 15 situations.

A part of the molecular mechanism of the type-I allergy response is being made clear, on the other hand, as described above. However, the signal transduction mechanism involved in degranulation of mast cell 20 through the high affinity IgE receptor has not been known yet. It is inevitable to elucidate the molecule involved in the degranulation process of mast cell not only for elucidating the molecular mechanism of the allergy response but also for developing therapeutic methods or therapeutic agents of the allergic diseases. Particularly, since the mast 25 cell plays a critical role in expression of the allergic conditions, the signal transducer that is specifically expressed in mast cell is quite important for developing novel antiallergic agents that selectively block the Fcε receptor signal transduction system that causes the degranulation reaction involving release of histamine and serotonin.

30

The object of the present invention performed based on the foregoing situations is to provide signal transducers specifically expressed in mouse and human mast cells, and polynucleotides (cDNAs)

encoding these protein molecules.

Another object of the present invention is to provide various genetic engineering materials involved in the signal transducers.

5

Disclosure of Invention

For solving the problems above, the present invention provides
10 the following inventions (1) to (10).

(1) A signal transducer specifically expressed in mouse mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 2.

15

(2) A signal transducer specifically expressed in human mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 4.

20 (3) A polynucleotide consisting of the base sequence of SEQ ID No. 1, which encodes the protein of (1).

(4) A polynucleotide having the base sequence of SEQ ID No. 3, which encodes the protein of (2).

25

(5) An expression vector involving the polynucleotide of (3).

(6) An expression vector involving the polynucleotide of (4).

30 (7) A cell transformed with the expression vector of (5), which produces the protein of (6).

(8) A cell transformed with the expression vector of (6), which

produces the protein of (2).

(9) An antibody specific for the protein of (1).

5 (10) An antibody specific for the protein of (2).

Brief Description of the Drawings

10 Fig. 1 shows the results of Northern blot analysis investigating expression of MIST, BASH and SLP-76 in the hemopoietic and non-hemopoietic cell lines. 18-18: B-precursor cells, WEHI1279: B cells, L1210: B-lymphocyte precursor cells, J558L and P3U1: plasma cells, EL-4 and BW5147: T cells, P388D1 and WEHI3: macrophages, P815: mast cell,
15 B8/3: erythroblast, and B16,Y1, NIH3T3 and ES-E14: non-hemopoietic cell lines.

Fig. 2 shows the results of RT-PCR analysis investigating expression of MIST in various hemopoietic cell lines.

20

Figs. 3 and 4 show the results of immunohistological analysis investigating expression of MIST in inflammatory mast cell in atopic dermatitis of the NC/Nga mouse.

25 Fig. 5 shows the results of degranulation reaction of RBL-2H3 clone expressing wild-type or mutant MIST.

Best Mode for Carrying Out the Invention

30

By screening the expression sequence tag (EST) database, the present inventor identified an EST clone from 13.5 day mouse embryo cDNA library (GenBank™ accession No. AA166259) which showed a

significant amino acid homology to the SH2 domain of chicken BASH (J. Immunol. 161:5804-5808, 1998). The inventor further found that the 1.8 kb mRNA of this clone is not expressed in other hemopoietic cell lines and non-hemopoietic cell lines (such as B cell, T cell and macrophages) in which BASH and SLP-76 are expressed, and is expressed only in mastcytoma cell line P815 (Fig. 1). The expressed protein molecule was named as MIST (Mast Cell-specific Immunoreceptor Signal Transducer) form such specific expression pattern and its function to be described hereinafter.

10

Embodiments of the present invention will be described in detail hereinafter.

The MISTs according to the inventions (1) and (2) are proteins that are specifically expressed in mouse and human mast cells. The mouse MIST in the invention (1) is a protein encoded in the polynucleotide (full-length cDNA: SEQ ID No. 1) of the invention (3). The human MIST in the invention (2) is, on the other hand, a protein encoded in the polynucleotide of the invention (4) containing the sequence of SEQ ID No. 3 (a partial cDNA).

20

While the mouse MIST in the invention (1) and human MIST in the invention (2) may be obtained by a method for isolating from organs and cell lines of mouse and human, respectively, by a method for preparing a peptide by a chemical synthesis based on the amino acid sequences provided by the present invention, or by a production method using a recombinant DNA technology using the polynucleotides of the inventions (3) and (4), the recombinant DNA method is preferably used. For example, RNA is prepared by in vitro transcription from a vector having the polynucleotides of the inventions (3) and (4), and MIST is expressed in vitro by in vitro translation using the RNA as a template. The mouse MIST and human MIST encoded by the polynucleotide can be expressed in large scale in prokaryotic cells such as E. coli and Bacillus subtilis, and

25

30

in eukaryotic cells such as yeast, insect cells, mammal cells and plant cells by recombination of the coding region with the expression vector using a conventional method.

5 The polynucleotide (SEQ ID No. 1) of the invention (3) can be obtained by a chemical synthesis or screening of the mouse cDNA library. For cloning the desired polynucleotide from a cDNA library, an oligonucleotide is synthesized based on the base sequence in an arbitrary portion of SEQ ID No. 1, and the polynucleotide is screened by colony or
10 plaque hybridization by the method known in the art using the oligonucleotide as a probe. Alternatively, oligonucleotides that can hybridize to both ends of the desired polynucleotide are synthesized, and the polynucleotide of the invention (3) is prepared by a PCR method using the oligonucleotides as primers and genomic DNA isolated from the mouse cells
15 as a template.

 The polynucleotide of the invention (4) can be prepared by isolating a full-length cDNA by hybridization screening or PCR using the oligonucleotides synthesized based on the base sequence at an arbitrary
20 portion of SEQ ID No. 3.

 For producing the MIST by expressing the polynucleotide in vitro translation, for example, the polynucleotide of the invention (3) or (4) is recombined into a vector having a RNA polymerase promoter [the inventions
25 (5) and (6)], and the recombinant vector is added to an in vitro translation system such as a lysate of rabbit reticulocytes or wheat germ extract containing the RNA polymerase corresponding to the promoter, thereby producing the mouse and human MIST in vitro. Examples of the RNA polymerase promoters include T7, T3 and SP6. Examples of the vectors
30 containing the RNA polymerase are pKA1, pCDM8, pT3/T7 18, pT7/3 19 and pBluescript™ II.

 For producing the MIST by expressing the polynucleotide in

microorganisms such as *E. coli*, an expression vector [the invention (5) and (6)] is prepared by recombining the polynucleotide of the invention (3) or (4) into an expression vector having an origin capable of replication in microorganisms, a promoter, a ribosome binding site, DNA cloning sites and terminator. After transforming host cell with this expression vector, the transformant obtained [the inventions (7) and (8)] is cultured for large scale production of MIST encoded by these polynucleotides in microorganisms. MIST fragments containing arbitrary regions may be obtained by adding an initiation codon and a termination codon before and after the arbitrary coding region. Or, the protein can be expressed as a fusion protein with other proteins. Only the protein regions encoded by this cDNA may be obtained by cleaving the fusion protein with an appropriate protease. Examples of the expression vector for use in *E. coli* include a pUC series vector, pBluescript II, pET expression system and pGEX expression system.

For producing the MIST by expressing the polynucleotide in eukaryotic cell, the polynucleotide of the invention (3) or (4) is recombined with an expression vector for eukaryotic cells that comprises a promoter, splicing site, poly(A) additional site to prepare a recombinant vector [the inventions (5) and (6)], and the vector is introduced into the eukaryotic cell to transform a host cell [the inventions (7) and (8)]. Examples of the expression vectors include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS and pYES2. MIST may be expressed as a fusion protein to which various tags such as His tag, FLAG tag and GFP by using pIND/V5-His, pFLAG-CMV-2, pEGFP-N1 and pEGFP-C1 as an expression vector. While cultured cells of a mammal such as monkey kidney cells COS7 and Chinese hamster ovary cells CHO, budding yeast, dividing yeast, silkworm cells and African clawed frog egg cells are usually used as the eukaryotic cells, any eukaryotic cells may be used so long as they are able to express MIST. The expression vector can be introduced into the eukaryotic cell by a conventional method such as an electroporation method, a calcium phosphate method, a liposome

method, and a DEAE dextran method.

A combination of separation methods known in the art may be used for purifying the desired protein from the culture after allowing
5 MIST to express in the prokaryotic cells and eukaryotic cells. For example, these methods include treatment with a denaturation reagent such as urea or with a surface active agent, ultrasonic treatment, enzymatic digestion, salting-out and solvent precipitation method, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE,
10 isoelectric focusing electrophoresis, ion exchange chromatography, hydrophobic chromatography, affinity chromatography and reversed phase chromatography.

The mouse MIST of the invention (1) and the human MIST of the
15 invention (2) contain any peptide fragments (five amino acid residues or more) represented by SEQ ID Nos. 2 and 4. These peptide fragments may be used for preparing antibodies. The MISTs of the inventions (1) and (2) are modified in any ways in the cell after translation. Accordingly, these modified proteins are also included within the scope of
20 the present invention. Examples of modification after translation include elimination of N-terminal methionine, N-terminal acetylation, addition of sugar chains, restricted degradation by an intracellular protease, addition of miristoleic acid, isoprenylation and phosphorylation.

25

Polymorphism by individual differences is often observed in the animal gene. Accordingly, polynucleotides having addition or deletion of one or plural nucleotides and/or substitution with other nucleotides in the base sequence of SEQ ID Nos. 1 and 3 are also included within the
30 scope of the present invention.

Likewise, MISTs having addition or deletion of one or plural amino acids and/or substitution with other amino acids caused by the

alteration of polynucleotides as described above are also included within the scope of the present invention so long as it has an activity of the MIST containing the amino acid sequences of SEQ ID Nos. 2 and 4.

5 The polynucleotides in the inventions (3) and (4) also include DNA fragments (10 bp or more) comprising any partial base sequence of SEQ ID Nos. 1 and 3. DNA fragments comprising sense strand and antisense strands are also included within the scope as described above.

10 The antibodies according to the inventions (9) and (10) can be obtained from serums of an animals immunized with the proteins of the inventions (1) and (2). Chemically synthesized peptides based on the amino acid sequences of SEQ ID Nos. 2 and 4, and MIST itself expressed in the eukaryotic or prokaryotic cells may be used for the antigen.
15 Otherwise, the antibodies may be produced from collected serums after introducing the expression vector for the eukaryotic cell into the muscle or skin of an animal by injection or using a gene gun (for example, the method described in Japanese Patent Publication No. 7-31387). The animals used include mouse, rat, rabbit, goat and chicken. Monoclonal
20 antibodies against MIST can be obtained by preparing a hybridoma by fusing B cell extracted from an immunized animal with myeloma cells.

Examples

25

The present invention is described in more detail with Examples, the present invention is not restricted in any sense by the Examples as set forth below.

30

Example 1: cDNA cloning

Full-length mouse MIST cDNA was isolated from PT18 cDNA

library with 5'- and 3'-RACE (Marathon™ cDNA amplification kit, made by Clontech Co.), using primers prepared based on the sequence information of EST clone (GenBank™ accession No. AA166259). The partial cDNA of human MIST was amplified by PCR using mRNA prepared from human cord
5 blood mast cell (HCMC) cultured with IL-6 and the stem cell factor (SFC: Peprotech™) according to the method in "Blood 86:3705-3714, 1995.

The sequence of the cDNA obtained was determined by the method known in the art, confirming that the mouse MIST cDNA comprises the base
10 sequence represented by SEQ ID No. 1 and the human MIST partial cDNA comprises the base sequence represented by SEQ ID No. 3. It was also confirmed that the mouse MIST has the amino acid sequence represented by SEQ ID No. 2 with a molecular weight of about 60 kDa. Eight Tyr residues capable of phosphorylation are found in the mouse MIST from the
15 N-terminus to the central part. The C-terminal part contains an SH2 domain which is most similar to the SH2 domain of mouse BASH and SLP-76 in amino acid level (41% and 53% identities, respectively). In addition, the central part of MIST is rich in Pro residues, and contains SH3 domain-binding motif. Consequently, MIST was confirmed to have the
20 features as a signal molecule.

The human MIST showed, on the other hand, 60% homology with the mouse MIST in the amino acid level.

25

Example 2: Construction of expression vector

The coding region of the mouse MIST cDNA obtained in Example 1 was amplified by PCR, and the amplified region was inserted between the
30 EcoRI and Sal I sites of pCATneo expression vector (J. Immunol., 161:5804-5808, 1998) to construct a recombinant expression vector (pCATneo-MIST-WT).

The MIST mutant (MIST-YF) in which amino acids (Tyr) at 69, 96, 101, 153, 174 and 188 in SEQ ID No. 2 were substituted with other amino acids (Phe) was prepared by a PCR-based mutagenesis using a commercially available mutation kit (made by Stratagene Co.), and subcloned the MIST-YF
5 into the pCATneo to construct a recombinant expression vector (pCATneo-MIST-YF).

Example 3: Preparation of transformed cells

10

The rat mast cell line RBL-2H3 were transfected with the recombinant expression vectors pCATneo-MIST or pCATneo-MIST-YF prepared in Example 2 to prepare the transformed cell RBL-2H3-MIST and RBL-2H3-MIST-YF.

15

Example 4: Preparation of antibody

An anti-MIST antibody was prepared from a rabbit immunized with a
20 fusion protein of a polypeptide comprising the amino acid sequence 193-435 in SEQ ID No. 2 and glutathione-S-transferase (GST). The antisera were at first precleared with Sepharose™ beads coupled with GST alone, and then purified with an affinity column coupled with GST-MIST fusion protein. Specificity of the antibody purified with affinity chromatography was
25 confirmed by an immunoblot analysis on cell lysates from COS cells transfected with mouse MIST cDNA.

Example 5: Confirmation of MIST expression in various cell lines

30

Expression of the mouse and human MISTs obtained in Example 1 was confirmed by RT-PCR. The objective cells were IL-3-induced mouse bone marrow-derived mast cells (BMMC), mouse mast cell line PT18,

human mast cells (HCNC) cultured with SCF and IL-6, and other hemocyte cell lines (Jurkat: human T cell, Romas: human B cell, KU812: human basophil precursor cell, EOL-1: human eosinophil precursor cell).

5 The results are as shown in Fig. 2. Although expression of MIST was found in mast cells BMMC, PT18 and HCNC, other cell lines showed no expression.

10 By using the anti-MIST antibody prepared in Example 4, serial tissue sections of NC/Nga mice, which spontaneously develop atopic dermatitis (J. Immunol., 9:461-466, 1997) were stained to clarify whether MIST protein is expressed in normal mast cells in vivo. The results are shown in Figs. 3 and 4. Expression of MIST was observed in the inflammatory mast cells in the mouse.

15

 It was confirmed from the results as described above that MIST is a protein specifically expressed in mast cell.

20 **Example 6: Confirmation of phosphorylation of tyrosine in MIST**

 Phosphorylation of tyrosine in MIST by stimulating with FcεRI was investigated using the rat mast cell line RBL-2H3 in which signal transduction of FcεRI had been confirmed.

25

 The transformed cell RBL-2H3-MIST prepared in Example 3 was cultured with 10 μg of anti-DNP mouse IgE (made by Sigma Co.) for 1 hour, and the cells were stimulated with 100 ng/ml of DNP-HSA. The cells were lysed with 1% NP40 lysis buffer, and the lysate was subjected
30 to immune precipitation together with various antibodies.

 Tyrosine of the MIST molecule was phosphorylated by stimulating the Fcε receptor on the mast cell IgE and antigens, and MIST associate

with signal molecules such as PLC- γ and Vav. Consequently, the MIST molecule was confirmed to be a signal molecule existing at the downstream of the Fc ϵ receptor. MIST was evidently phosphorylated by Lyn kinase among tyrosine kinases present in the mast cell, showing that the Lyn kinase has an important role for degranulation of the mast cell.

Example 7: Investigation of MIST function in degranulation of mast cell

The effect of over expression of MIST and mutation type MIST on degranulation of the cells was investigated using the transformed cells RBL-2H3-MIST and RBL-2H3-MIST-YF prepared in Example 3.

The cells were cultured with 1 μ g/ml of anti-DNP mouse IgE overnight, washed twice with PBS, and stimulated with DNP-HSA at 37°C for 30 minutes. Degranulation was confirmed by measuring release of β -hexosaminidase by the method described in the literature (Int. Immunol., 7:251-258, 1992).

The results are shown in Fig. 5. Although degranulation of the mast cell was not affected by stimulation with the Fc ϵ receptor when a wild type MIST was over expressed, degranulation of the mast cell via the Fc ϵ receptor was significantly suppressed by over expression of the MIST mutant (MIST-YF).

It was confirmed from the results above that the MIST molecule plays an important role in the signal transduction pathway from stimulation by the Fc ϵ receptor through degranulation.

Industrial Applicability

The present invention provides signal transducers that are

specifically expressed in mouse and human mast cells, polynucleotides (cDNAs) encoding this protein molecule and various gene engineering materials concerning these signal transducers. Screening of novel agents for allergic diseases becomes possible by using these signal
5 transducers as targets.

SEQUENCE LISTING

<110> Japan Science and Technology Corporation

<120> Mast cell-specific signal transducing molecules and cDNAs thereof

<130> 9515-144CA FC/VC/vd

<140> 2,351,722

<141> 2000-09-18

<150> PCT/JP00/06351

<151> 2000-09-18

<150> JP 1999-263778

<151> 1999-09-17

<160> 4

<170> Patentln Ver. 2.0

<210> 1

<211> 1721

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (255)..(1562)

<300>

<301> Goitsuka R., et al.

<302> A BASH/SLP-76-related adaptor protein MIST/Clink involved in IgE receptor-mediated mast cell degranulation

<303> Int. Immunol.

<304> 12

<305> 4

<306> 573-580

<307> 2000

<308> GenBank/AB021220

<309> 2000-05-26

<400> 1

```

acgaggccaa actgcccagg tctgtggctg cgtttctcgg aaaacccaaaa ctcaacaggc 60
acatacaagg cactctctgc tgaaggactc tgctgagggg agagaacatg tcaactctat 120
cttacagagt gctccaggat ggcaccgtgg accccctttc caggagctag ccgtctcaac 180
actgagccct tgactaaagg aagactgagc aggetgagtt gaagatccct ctcttttgcc 240
aggtgccaaag gacc atg acc agc cag ggc aat aaa agg aca acg aaa gaa 290
                Met Thr Ser Gln Gly Asn Lys Arg Thr Thr Lys Glu
                1                5                10
gga ttc ggt gat ctg aga ttc cag aac gtc tct ctg ctg aaa aat agg 338
Gly Phe Gly Asp Leu Arg Phe Gln Asn Val Ser Leu Leu Lys Asn Arg
                15                20                25

```

tca	tgg	cca	agc	ctc	agc	agt	gcc	aaa	ggg	cgg	tgt	cga	gcg	gtt	ctg	386
Ser	Trp	Pro	Ser	Leu	Ser	Ser	Ala	Lys	Gly	Arg	Cys	Arg	Ala	Val	Leu	
	30					35				40						
gaa	cca	ctt	ccg	gat	cac	aga	agg	aac	ttg	gct	ggg	gtc	cca	ggg	gga	434
Glu	Pro	Leu	Pro	Asp	His	Arg	Arg	Asn	Leu	Ala	Gly	Val	Pro	Gly	Gly	
45					50				55						60	
gaa	aaa	tgc	aac	agt	aac	aac	gac	tac	gaa	gat	cct	gag	ttc	cag	ctg	482
Glu	Lys	Cys	Asn	Ser	Asn	Asn	Asp	Tyr	Glu	Asp	Pro	Glu	Phe	Gln	Leu	
			65					70						75		
ctg	aag	gca	tgg	cca	tca	atg	aaa	att	tta	cca	gcc	aga	cct	atc	cag	530
Leu	Lys	Ala	Trp	Pro	Ser	Met	Lys	Ile	Leu	Pro	Ala	Arg	Pro	Ile	Gln	
			80					85						90		
gaa	tcg	gaa	tac	gca	gat	aca	cgc	tat	ttc	cag	gat	atg	atg	gag	gct	578
Glu	Ser	Glu	Tyr	Ala	Asp	Thr	Arg	Tyr	Phe	Gln	Asp	Met	Met	Glu	Ala	
	95						100					105				
ccc	ctt	ctg	tta	cct	ccc	aag	gct	tct	gtc	tcc	act	gag	aga	caa	acc	626
Pro	Leu	Leu	Leu	Pro	Pro	Lys	Ala	Ser	Val	Ser	Thr	Glu	Arg	Gln	Thr	
	110					115					120					
agg	gat	gtg	agg	atg	aca	cag	ctg	gaa	gaa	gtg	gac	aag	cct	acc	ttc	674
Arg	Asp	Val	Arg	Met	Thr	Gln	Leu	Glu	Glu	Val	Asp	Lys	Pro	Thr	Phe	
125					130					135					140	
aag	gat	gtc	aga	agc	caa	cgc	ttt	aaa	gga	ttc	aaa	tac	aca	aaa	ata	722
Lys	Asp	Val	Arg	Ser	Gln	Arg	Phe	Lys	Gly	Phe	Lys	Tyr	Thr	Lys	Ile	
				145				150						155		
aac	aag	act	cct	ttg	cca	cct	cct	cgg	cct	gct	atc	act	ctc	ccc	aag	770
Asn	Lys	Thr	Pro	Leu	Pro	Pro	Pro	Arg	Pro	Ala	Ile	Thr	Leu	Pro	Lys	
			160					165						170		
aag	tac	caa	ccc	tta	ccc	cca	gca	cca	cca	gag	gag	agc	agt	gca	tac	818
Lys	Tyr	Gln	Pro	Leu	Pro	Pro	Ala	Pro	Pro	Glu	Glu	Ser	Ser	Ala	Tyr	
		175					180					185				
ttc	gct	cca	aag	ccc	acc	ttt	cca	gaa	gtc	cag	agg	ggg	ccc	agg	cag	866
Phe	Ala	Pro	Lys	Pro	Thr	Phe	Pro	Glu	Val	Gln	Arg	Gly	Pro	Arg	Gln	
	190					195					200					
agg	agt	gca	aaa	gac	ttc	agt	agg	gtc	ctt	gga	gca	gaa	gaa	gaa	tct	914
Arg	Ser	Ala	Lys	Asp	Phe	Ser	Arg	Val	Leu	Gly	Ala	Glu	Glu	Glu	Ser	
205				210						215					220	
cac	cac	cag	aca	aag	cca	gaa	tct	tct	tgc	cca	tca	tca	aac	caa	aac	962
His	His	Gln	Thr	Lys	Pro	Glu	Ser	Ser	Cys	Pro	Ser	Ser	Asn	Gln	Asn	
				225					230					235		
aca	cag	aag	agt	cca	cct	gcc	att	gcc	agc	tct	tcc	tac	atg	cca	gga	1010
Thr	Gln	Lys	Ser	Pro	Pro	Ala	Ile	Ala	Ser	Ser	Ser	Tyr	Met	Pro	Gly	
			240					245						250		
aag	cac	agt	ata	caa	gcc	aga	gac	cat	aca	ggg	agc	atg	cag	cac	tgt	1058
Lys	His	Ser	Ile	Gln	Ala	Arg	Asp	His	Thr	Gly	Ser	Met	Gln	His	Cys	
		255					260					265				
cct	gct	cag	aga	tgc	caa	gct	gca	gcc	agc	cac	agc	cct	cga	atg	ctg	1106
Pro	Ala	Gln	Arg	Cys	Gln	Ala	Ala	Ala	Ser	His	Ser	Pro	Arg	Met	Leu	
	270					275						280				
ccc	tat	gaa	aac	aca	aac	tcg	gag	aaa	cct	gac	ccc	aca	aag	cct	gat	1154
Pro	Tyr	Glu	Asn	Thr	Asn	Ser	Glu	Lys	Pro	Asp	Pro	Thr	Lys	Pro	Asp	
285					290					295					300	
gag	aag	gat	gtc	tgg	cag	aat	gaa	tgg	tac	att	gga	gaa	tac	agt	cgc	1202
Glu	Lys	Asp	Val	Trp	Gln	Asn	Glu	Trp	Tyr	Ile	Gly	Glu	Tyr	Ser	Arg	
				305					310					315		

```

cag gca gtg gaa gat gtg tta atg aaa gag aac aag gat ggt act ttt 1250
Gln Ala Val Glu Asp Val Leu Met Lys Glu Asn Lys Asp Gly Thr Phe
      320      325      330
ttg gtc cga gac tgc tct aca aaa tcc aag gca gaa cca tat gtt ttg 1298
Leu Val Arg Asp Cys Ser Thr Lys Ser Lys Ala Glu Pro Tyr Val Leu
      335      340      345
gtg gtg ttt tat ggg aac aag gtc tac aat gtg aaa atc cgt ttc ctc 1346
Val Val Phe Tyr Gly Asn Lys Val Tyr Asn Val Lys Ile Arg Phe Leu
      350      355      360
gag agc aat caa cag ttt gcc ctg ggc aca gga cta cga gga aat gag 1394
Glu Ser Asn Gln Gln Phe Ala Leu Gly Thr Gly Leu Arg Gly Asn Glu
      365      370      375      380
atg ttt gat tct gtg gaa gac atc att gaa cac tac aca tat ttt ccc 1442
Met Phe Asp Ser Val Glu Asp Ile Ile Glu His Tyr Thr Tyr Phe Pro
      385      390      395
att ctg cta ata gat ggg aaa gac aag gct gca cgc agg aaa cag tgc 1490
Ile Leu Leu Ile Asp Gly Lys Asp Lys Ala Ala Arg Arg Lys Gln Cys
      400      405      410
tac ctc acc cag cca ctg cct ctc gcc agg ctc ctt ctc act cag tac 1538
Tyr Leu Thr Gln Pro Leu Pro Leu Ala Arg Leu Leu Leu Thr Gln Tyr
      415      420      425
tcc agc cag gca ctt cat gag caa gaagcccagc cagatatccc cgcattcagtg 1592
Ser Ser Gln Ala Leu His Glu
      430      435
gcctgggcct tgtctcattc ctggetcaat ggattcagtt cttcttccat ctgcatttat 1652
ctgcaaagta ttattttctg tgtcttcaag ggatgatttt ttgactctgt aaaaaaaaaa 1712
aaaaaaaaaa 1721

```

<210> 2
 <211> 435
 <212> PRT
 <213> Mus musculus

```

<400> 2
Met Thr Ser Gln Gly Asn Lys Arg Thr Thr Lys Glu Gly Phe Gly Asp
  1      5      10      15
Leu Arg Phe Gln Asn Val Ser Leu Leu Lys Asn Arg Ser Trp Pro Ser
      20      25      30
Leu Ser Ser Ala Lys Gly Arg Cys Arg Ala Val Leu Glu Pro Leu Pro
      35      40      45
Asp His Arg Arg Asn Leu Ala Gly Val Pro Gly Gly Glu Lys Cys Asn
      50      55      60
Ser Asn Asn Asp Tyr Glu Asp Pro Glu Phe Gln Leu Leu Lys Ala Trp
      65      70      75      80
Pro Ser Met Lys Ile Leu Pro Ala Arg Pro Ile Gln Glu Ser Glu Tyr
      85      90      95
Ala Asp Thr Arg Tyr Phe Gln Asp Met Met Glu Ala Pro Leu Leu Leu
      100      105      110
Pro Pro Lys Ala Ser Val Ser Thr Glu Arg Gln Thr Arg Asp Val Arg
      115      120      125
Met Thr Gln Leu Glu Glu Val Asp Lys Pro Thr Phe Lys Asp Val Arg
      130      135      140
Ser Gln Arg Phe Lys Gly Phe Lys Tyr Thr Lys Ile Asn Lys Thr Pro
      145      150      155      160

```

```

Leu Pro Pro Pro Arg Pro Ala Ile Thr Leu Pro Lys Lys Tyr Gln Pro
      165                      170                      175
Leu Pro Pro Ala Pro Pro Glu Glu Ser Ser Ala Tyr Phe Ala Pro Lys
      180                      185                      190
Pro Thr Phe Pro Glu Val Gln Arg Gly Pro Arg Gln Arg Ser Ala Lys
      195                      200                      205
Asp Phe Ser Arg Val Leu Gly Ala Glu Glu Glu Ser His His Gln Thr
      210                      215                      220
Lys Pro Glu Ser Ser Cys Pro Ser Ser Asn Gln Asn Thr Gln Lys Ser
225                      230                      235                      240
Pro Pro Ala Ile Ala Ser Ser Ser Tyr Met Pro Gly Lys His Ser Ile
      245                      250                      255
Gln Ala Arg Asp His Thr Gly Ser Met Gln His Cys Pro Ala Gln Arg
      260                      265                      270
Cys Gln Ala Ala Ala Ser His Ser Pro Arg Met Leu Pro Tyr Glu Asn
      275                      280                      285
Thr Asn Ser Glu Lys Pro Asp Pro Thr Lys Pro Asp Glu Lys Asp Val
      290                      295                      300
Trp Gln Asn Glu Trp Tyr Ile Gly Glu Tyr Ser Arg Gln Ala Val Glu
305                      310                      315                      320
Asp Val Leu Met Lys Glu Asn Lys Asp Gly Thr Phe Leu Val Arg Asp
      325                      330                      335
Cys Ser Thr Lys Ser Lys Ala Glu Pro Tyr Val Leu Val Val Phe Tyr
      340                      345                      350
Gly Asn Lys Val Tyr Asn Val Lys Ile Arg Phe Leu Glu Ser Asn Gln
      355                      360                      365
Gln Phe Ala Leu Gly Thr Gly Leu Arg Gly Asn Glu Met Phe Asp Ser
      370                      375                      380
Val Glu Asp Ile Ile Glu His Tyr Thr Tyr Phe Pro Ile Leu Leu Ile
385                      390                      395                      400
Asp Gly Lys Asp Lys Ala Ala Arg Arg Lys Gln Cys Tyr Leu Thr Gln
      405                      410                      415
Pro Leu Pro Leu Ala Arg Leu Leu Leu Thr Gln Tyr Ser Ser Gln Ala
      420                      425                      430
Leu His Glu
      435

```

<210> 3

<211> 1129

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1128)

<300>

<301> Goitsuka R., et al.

<302> A BASH/SLP-76-related adaptor protein MIST/Clink involved
in IgE receptor-mediated mast cell degranulation

<303> Int. Immunol.

<304> 12

<305> 4

<306> 573-580

<307> 2000

<308> GenBank/AB021220

<309> 2000-05-26

<400> 3

ttc	cag	aac	ttc	agt	ctg	cca	aaa	aac	agg	tca	tgg	cct	cgc	atc	aat	48
Phe	Gln	Asn	Phe	Ser	Leu	Pro	Lys	Asn	Arg	Ser	Trp	Pro	Arg	Ile	Asn	
1				5					10					15		
agt	gcc	aca	ggc	cag	tac	cag	agg	atg	aac	aag	cct	ctt	cta	gac	tgg	96
Ser	Ala	Thr	Gly	Gln	Tyr	Gln	Arg	Met	Asn	Lys	Pro	Leu	Leu	Asp	Trp	
			20					25					30			
gaa	aga	aac	ttt	gct	gca	gtc	ctg	gat	gga	gca	aaa	ggc	cac	agt	gat	144
Glu	Arg	Asn	Phe	Ala	Ala	Val	Leu	Asp	Gly	Ala	Lys	Gly	His	Ser	Asp	
		35					40					45				
gat	gac	tat	gat	gac	cct	gag	ctt	cgg	atg	gaa	gag	aca	tgg	cag	tcg	192
Asp	Asp	Tyr	Asp	Asp	Pro	Glu	Leu	Arg	Met	Glu	Glu	Thr	Trp	Gln	Ser	
	50					55				60						
att	aaa	att	tta	cca	gcc	cgg	cct	ata	aag	gaa	tct	gaa	tat	gca	gat	240
Ile	Lys	Ile	Leu	Pro	Ala	Arg	Pro	Ile	Lys	Glu	Ser	Glu	Tyr	Ala	Asp	
65					70				75					80		
aca	cac	tat	ttc	aag	gtt	gca	atg	gac	act	ccc	ctt	ccg	tta	gac	acc	288
Thr	His	Tyr	Phe	Lys	Val	Ala	Met	Asp	Thr	Pro	Leu	Pro	Leu	Asp	Thr	
				85				90					95			
agg	acc	tct	atc	tcc	att	gga	cag	ccg	acc	tgg	aac	aca	cag	acg	agg	336
Arg	Thr	Ser	Ile	Ser	Ile	Gly	Gln	Pro	Thr	Trp	Asn	Thr	Gln	Thr	Arg	
			100					105					110			
ttg	gaa	aga	gtg	gac	aaa	ccc	att	tcc	agg	gac	gtc	aga	agc	caa	aac	384
Leu	Glu	Arg	Val	Asp	Lys	Pro	Ile	Ser	Arg	Asp	Val	Arg	Ser	Gln	Asn	
		115					120					125				
att	aaa	gga	gat	gca	tcc	gta	aga	aag	aac	aag	att	cct	tta	cca	cct	432
Ile	Lys	Gly	Asp	Ala	Ser	Val	Arg	Lys	Asn	Lys	Ile	Pro	Leu	Pro	Pro	
	130					135				140						
cct	cgg	cct	ctc	ata	aca	ctt	ccg	aag	aag	tac	caa	ccc	ttg	ccc	cct	480
Pro	Arg	Pro	Leu	Ile	Thr	Leu	Pro	Lys	Lys	Tyr	Gln	Pro	Leu	Pro	Pro	
145					150					155				160		
gag	ccg	gag	agc	agc	agg	cca	cct	tta	tct	cag	aga	cac	acc	ttt	cca	528
Glu	Pro	Glu	Ser	Ser	Arg	Pro	Pro	Leu	Ser	Gln	Arg	His	Thr	Phe	Pro	
			165					170					175			
gaa	gtc	cag	gga	atg	ccc	agt	cag	ata	agc	tta	agg	gac	tta	agt	gag	576
Glu	Val	Gln	Gly	Met	Pro	Ser	Gln	Ile	Ser	Leu	Arg	Asp	Leu	Ser	Glu	
			180					185					190			
gtc	ctt	gaa	gca	gaa	aaa	gtt	cct	cat	aac	cag	agg	aag	cct	gaa	tca	624
Val	Leu	Glu	Ala	Glu	Lys	Val	Pro	His	Asn	Gln	Arg	Lys	Pro	Glu	Ser	
		195					200					205				
act	cat	ctg	tta	gaa	aac	caa	aat	act	caa	gag	att	cca	ctt	gcc	att	672
Thr	His	Leu	Leu	Glu	Asn	Gln	Asn	Thr	Gln	Glu	Ile	Pro	Leu	Ala	Ile	
		210				215					220					
agc	agt	tct	tca	ttc	acg	aca	agc	aac	cac	agt	gtg	caa	aac	aga	gat	720
Ser	Ser	Ser	Ser	Phe	Thr	Thr	Ser	Asn	His	Ser	Val	Gln	Asn	Arg	Asp	
225					230					235				240		
cat	aga	gga	ggc	atg	cag	ccc	tgt	tct	cct	cag	aga	tgc	cag	cct	cca	768
His	Arg	Gly	Gly	Met	Gln	Pro	Cys	Ser	Pro	Gln	Arg	Cys	Gln	Pro	Pro	
			245					250					255			
gcc	agc	tgc	agc	cct	cac	gaa	aat	ata	ctg	ccc	tat	aaa	tac	aca	agc	816
Ala	Ser	Cys	Ser	Pro	His	Glu	Asn	Ile	Leu	Pro	Tyr	Lys	Tyr	Thr	Ser	
			260					265					270			

tgg	aga	cca	cct	ttc	ccc	aaa	agg	tct	gat	aga	aag	gat	gtc	cag	cac	864
Trp	Arg	Pro	Pro	Phe	Pro	Lys	Arg	Ser	Asp	Arg	Lys	Asp	Val	Gln	His	
		275					280				285					
aat	gaa	tgg	tac	att	gga	gaa	cac	agc	cgc	cag	gca	gtg	gaa	gag	gca	912
Asn	Glu	Trp	Tyr	Ile	Gly	Glu	Tyr	Ser	Arg	Gln	Ala	Val	Glu	Glu	Ala	
	290					295				300						
ttc	atg	aag	gag	aac	aag	gat	ggg	agt	ttc	ttg	gtc	cga	gat	tgt	tcc	960
Phe	Met	Lys	Glu	Asn	Lys	Asp	Gly	Ser	Phe	Leu	Val	Arg	Asp	Cys	Ser	
305					310					315					320	
aca	aaa	tcc	aag	gaa	gag	ccc	cat	gtt	ttg	gct	gtg	ttt	tat	gag	aac	1008
Thr	Lys	Ser	Lys	Glu	Glu	Pro	Tyr	Val	Leu	Ala	Val	Phe	Tyr	Glu	Asn	
				325					330					335		
aaa	gtc	tac	aat	gta	aaa	atc	cgc	ttc	ctg	gag	agg	aat	cag	cag	ttt	1056
Lys	Val	Tyr	Asn	Val	Lys	Ile	Arg	Phe	Leu	Glu	Arg	Asn	Gln	Gln	Phe	
			340				345					350				
gcc	ctg	ggg	aca	gga	ctc	aga	gga	gat	gag	aag	ttt	gat	tca	gta	gaa	1104
Ala	Leu	Gly	Thr	Gly	Leu	Arg	Gly	Asp	Glu	Lys	Phe	Asp	Ser	Val	Glu	
		355				360						365				
gac	atc	atc	gaa	cac	tac	aag	aat	t								1129
Asp	Ile	Ile	Glu	His	Tyr	Lys	Asn									
	370					375										

<210> 4

<211> 376

<212> PRT

<213> Homo sapiens

<400> 4


Phe	Gln	Asn	Phe	Ser	Leu	Pro	Lys	Asn	Arg	Ser	Trp	Pro	Arg	Ile	Asn	
1				5					10					15		
Ser	Ala	Thr	Gly	Gln	Tyr	Gln	Arg	Met	Asn	Lys	Pro	Leu	Leu	Asp	Trp	
			20					25					30			
Glu	Arg	Asn	Phe	Ala	Ala	Val	Leu	Asp	Gly	Ala	Lys	Gly	His	Ser	Asp	
		35				40						45				
Asp	Asp	Tyr	Asp	Asp	Pro	Glu	Leu	Arg	Met	Glu	Glu	Thr	Trp	Gln	Ser	
	50					55					60					
Ile	Lys	Ile	Leu	Pro	Ala	Arg	Pro	Ile	Lys	Glu	Ser	Glu	Tyr	Ala	Asp	
65				70						75					80	
Thr	His	Tyr	Phe	Lys	Val	Ala	Met	Asp	Thr	Pro	Leu	Pro	Leu	Asp	Thr	
				85					90					95		
Arg	Thr	Ser	Ile	Ser	Ile	Gly	Gln	Pro	Thr	Trp	Asn	Thr	Gln	Thr	Arg	
			100					105					110			
Leu	Glu	Arg	Val	Asp	Lys	Pro	Ile	Ser	Arg	Asp	Val	Arg	Ser	Gln	Asn	
		115				120					125					
Ile	Lys	Gly	Asp	Ala	Ser	Val	Arg	Lys	Asn	Lys	Ile	Pro	Leu	Pro	Pro	
	130					135					140					
Pro	Arg	Pro	Leu	Ile	Thr	Leu	Pro	Lys	Lys	Tyr	Gln	Pro	Leu	Pro	Pro	
145					150					155					160	
Glu	Pro	Glu	Ser	Ser	Arg	Pro	Pro	Leu	Ser	Gln	Arg	His	Thr	Phe	Pro	
				165					170					175		
Glu	Val	Gln	Gly	Met	Pro	Ser	Gln	Ile	Ser	Leu	Arg	Asp	Leu	Ser	Glu	
			180					185					190			
Val	Leu	Glu	Ala	Glu	Lys	Val	Pro	His	Asn	Gln	Arg	Lys	Pro	Glu	Ser	
		195					200					205				

Thr	His	Leu	Leu	Glu	Asn	Gln	Asn	Thr	Gln	Glu	Ile	Pro	Leu	Ala	Ile
210						215					220				
Ser	Ser	Ser	Ser	Phe	Thr	Thr	Ser	Asn	His	Ser	Val	Gln	Asn	Arg	Asp
225					230					235					240
His	Arg	Gly	Gly	Met	Gln	Pro	Cys	Ser	Pro	Gln	Arg	Cys	Gln	Pro	Pro
				245					250					255	
Ala	Ser	Cys	Ser	Pro	His	Glu	Asn	Ile	Leu	Pro	Tyr	Lys	Tyr	Thr	Ser
			260					265					270		
Trp	Arg	Pro	Pro	Phe	Pro	Lys	Arg	Ser	Asp	Arg	Lys	Asp	Val	Gln	His
		275					280					285			
Asn	Glu	Trp	Tyr	Ile	Gly	Glu	Tyr	Ser	Arg	Gln	Ala	Val	Glu	Glu	Ala
290						295					300				
Phe	Met	Lys	Glu	Asn	Lys	Asp	Gly	Ser	Phe	Leu	Val	Arg	Asp	Cys	Ser
305					310					315					320
Thr	Lys	Ser	Lys	Glu	Glu	Pro	Tyr	Val	Leu	Ala	Val	Phe	Tyr	Glu	Asn
				325					330					335	
Lys	Val	Tyr	Asn	Val	Lys	Ile	Arg	Phe	Leu	Glu	Arg	Asn	Gln	Gln	Phe
			340					345					350		
Ala	Leu	Gly	Thr	Gly	Leu	Arg	Gly	Asp	Glu	Lys	Phe	Asp	Ser	Val	Glu
		355					360					365			
Asp	Ile	Ile	Glu	His	Tyr	Lys	Asn								
370						375									


CLAIMS

1. A signal transducer specifically expressed in mouse mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 2.
2. A signal transducer specifically expressed in human mast cells, which is a purified protein having the amino acid sequence of SEQ ID No. 4.
3. A polynucleotide consisting of the base sequence of SEQ ID No. 1, which encodes the protein of claim 1.
4. A polynucleotide having the base sequence of SEQ ID No. 3, which encodes the protein of claim 2.
5. An expression vector comprising the polynucleotide of claim 3.
6. An expression vector comprising the polynucleotide of claim 4.
7. A cell transformed with the expression vector of claim 5, which produces the protein of claim 1.
8. A cell transformed with the expression vector of claim 6, which produces the protein of claim 2.
9. An antibody specific for the protein of claim 1.
10. An antibody specific for the protein of claim 2.

1/3

Fig. 1

2/3

Fig. 2*Fig. 3**Fig. 4*

*3/3**Fig. 5*